HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Canada regulates siloxanes

This article was originally published in The Rose Sheet

Executive Summary

The Canadian environment ministry has declared D4 and D5 siloxanes "substances of concern" and will set a concentration threshold for the ingredients, which are found in many personal-care products, Environment Canada announces Jan. 30. The limit will be developed for consumer products and for wastewater under Canada's Chemical Management Plan. The Canadian government says that while siloxanes are not a risk to human health when used in personal-care products, they are entering the environment in "relatively large quantities" and may harm fish and aquatic organisms. Environmental Working Group notes that this move is the first action against siloxanes taken by any country and urges U.S. Environmental Protection Agency to conduct an assessment of the chemicals, asserting that their persistence in the environment may cause them to enter the food chain and could pose "significant, long-term risks to human health as well." Canada requires nanotech data: Health Canada is poised to implement rules that would require companies to detail their use of engineered nanomaterials, according to the Project on Emerging Nanotechnologies of the Woodrow Wilson Center for Scholars. Canada will be the first country in the world to take such action, PEN says. Companies that manufactured or imported more than one kilogram of nanomaterials during 2008 will be subject to the one-time request; information submitted will be used by Canadian regulatory authorities to determine the risks of nanomaterials and to guide the development of appropriate environmental, health and safety requirements. "This decision by Canada-to establish the world's first national mandatory nanoscale materials reporting requirement for companies-is an important step toward ensuring that nanotechnology regulation is driven by accurate information and high-quality science," says Andrew Maynard, PEN chief science advisor

You may also be interested in...



Campaign comes down on FDA

"FDA appears to still be operating under Bush-era tactics of secrecy and delay," based on the absence of any public statement, report or action from the agency related to lead in popular lipstick brands, which the Campaign for Safe Cosmetics brought to FDA's attention more than a year ago, rep Stacy Malkan says. On the other hand, the Canadian government is evaluating next steps after notifying public of lead in children's face paint, Campaign says, also pointing to Canada's action with regard to D4 and D5 siloxanes - which have been named "substances of concern" due to their environmental impact - as evidence that FDA is lagging behind its neighbor when it comes to personal-care regulation (1"The Rose Sheet" Feb. 9, 2009, In Brief). FDA "does not conduct routine safety testing of personal-care products and does not publicly report information in a timely manner - as evidenced by the lead-in-lipstick situation," the watchdog group says. The Campaign's October 2007 "Poison Kiss" study detected lead in 61% of lipsticks tested; three senators including John Kerry, D-Mass., reacted with a letter to FDA requesting that the agency "take immediate action" to protect the public. However, the American Council on Science and Health went on to name "toxic lipstick" the No. 1 "unfounded health scare" of 2007, and in March 2008 the California Attorney General recommended against Prop 65 action targeting manufacturers of lipsticks with lead concentrations lower than 5 ppm (2"The Rose Sheet" Jan. 7, 2008, p. 4). The Campaign maintains that "lead in any amount is a health concern ... and pregnant women and children are particularly vulnerable.

Data For Two HER2-Positive Breast Cancer Drugs Impress, Including On Overall Survival

AstraZeneca/Daiichi Sankyo and Seattle Genetics presented exciting data at SABCS on drugs that extended survival in patients who had exhausted most treatment options.

The FDA Builds On Lessons Learned In Rebuilding Quality Metrics Program

US FDA officials tell industry that implementing a quality metrics program is an agency priority and that a rejiggered program will incorporate various elements of other quality metrics initiatives being piloted by the agency, industry and academia.

UsernamePublicRestriction

Register

RS015942

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel